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This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).SUMMARYVa24 invariant natural killer T (iNKT) cells are a subset of T lymphocytes implicated in the regulation of broad immune responses. They
recognize lipid antigens presented by CD1d on antigen-presenting cells and induce both innate and adaptive immune responses, which
enhance effective immunity against cancer. Conversely, reduced iNKT cell numbers and function have been observed in many patients
with cancer. To recover these numbers, we reprogrammed human iNKTcells to pluripotency and then re-differentiated them into regen-
erated iNKT cells in vitro through an IL-7/IL-15-based optimized cytokine combination. The re-differentiated iNKT cells showed prolif-
eration and IFN-g production in response to a-galactosylceramide, induced dendritic cell maturation and downstream activation of both
cytotoxic T lymphocytes and NK cells, and exhibited NKG2D- and DNAM-1-mediated NK cell-like cytotoxicity against cancer cell lines.
The immunological features of re-differentiated iNKT cells and their unlimited availability from induced pluripotent stem cells offer a
potentially effective immunotherapy against cancer.INTRODUCTION
Cytotoxic T lymphocytes (CTLs) play a crucial role in the
eradication of cancer cells by precisely recognizing them
via tumor antigen-specific T cell receptors (TCRs) in a pep-
tide-dependent, human leukocyte antigen (HLA)-restricted
manner (Maus et al., 2014). Sometimes, however, cancer
cells can proliferate due to absent or dysfunctional CTLs,
thus creating demand for immunotherapies. We and
another group recently reported the unlimited production
of target antigen-specific humanCD8+ T lymphocytes from
induced pluripotent stem cells (iPSCs) (Nishimura et al.,
2013; Vizcardo et al., 2013). This technology has the poten-
tial to overcome two important problems currently facing
T cell immunotherapies: a shortage of tumor antigen-spe-
cific T cells and their exhaustion induced by continuous
TCR stimulation and overproliferation (Schietinger and
Greenberg, 2014). However, other problems in Tcell immu-
notherapies must also be overcome. One example is the
emergence of tumor escape from antigen-specific mono-
clonal CTLs due to tumor immune-editing involving tu-
mor antigen mutagenesis or HLA depression (Schreiber
et al., 2011). Another problem is local immunosuppressionStem Cein the tumor microenvironment by instigated immune
cells, which supports tumor growth and inhibits CTL activ-
ities (Mittal et al., 2014; Motz and Coukos, 2013; Noy and
Pollard, 2014). A good approach to overcome these prob-
lems would be combination therapy using a cellular adju-
vant, i.e., invariant natural killer T (iNKT) cells, as iNKT
cells exert helper functions to induce antigen-specific poly-
clonal CTLs (Cerundolo et al., 2009), improve the immu-
nosuppressive milieu (De Santo et al., 2010), and maintain
memory CD8+ T cells (Hong et al., 2009).
iNKT cells are a unique subset of T cells that express a ca-
nonical invariant TCR a chain (Va24-Ja18 in humans) and
TCR b chains that use limited Vb segments (Vb11 in hu-
mans), and also play a key role in the regulation of innate
and adaptive immunity (Berzins et al., 2011; Brennan
et al., 2013). In contrast to conventional ab T cells, iNKT
cells recognize a limited number of lipid antigens presented
by the MHC class I-like molecule CD1d. Stimulation of
iNKT cells by a-galactosylceramide (a-GalCer), a synthetic
glycosphingolipid, results in the rapid production of Th1
and Th2 cytokines (e.g., interleukin-g [IFN-g] and inter-
leukin-4 [IL-4]) and increased expression of CD40 ligand
(CD40L), which induces dendritic cell (DC) maturationll Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Authors 213
and production of IL-12p70 (Liu et al., 2008; McEwen-
Smith et al., 2015; Uemura et al., 2009). These events ulti-
mately lead to downstream activation of critical effectors
of antitumor immunity, including NK cells, CTLs, and Th
cells (Hong et al., 2009; Salio et al., 2014). Because CD1d
is non-polymorphic, the modification of DC function by
iNKT cells is independent of HLA restriction, making this
process attractive for broad clinical application.
The antitumor potential of iNKT cells has been demon-
strated in several clinical trials (Chang et al., 2005;
McEwen-Smith et al., 2015; Motohashi et al., 2006, 2009;
Nicol et al., 2011; Richter et al., 2013; Song et al., 2009;
Uchida et al., 2008; Yamasaki et al., 2011). Infiltration of
iNKT cells into tumor tissue is a favorable prognostic factor
and is associatedwith improved survival,while low levels of
circulating iNKT cells predict a poor clinical outcome (Mol-
ling et al., 2007). Although human iNKT cells are present
wherever conventional T cells are found, their frequency
relative to other T cells is less than 0.1%. In addition, a defi-
ciency of iNKT cells and/or defects in their function has
been reported in patients with many types of cancer (Ber-
zins et al., 2011; Molling et al., 2005). Consequently,
acquiring sufficient numbers of iNKT cells from patients
to induce effective antitumor immune responses is
currently an obstacle to iNKT cell-based immunotherapy.
Aprevious studyhas shown that iNKTcell TCR-harboring
mouse iPSCs candifferentiate intomature iNKTcells in vivo
(Watarai et al., 2010). It remains unclear, however, whether
human iNKT cell-derived iPSCs can differentiate into
functional iNKTcells ex vivo. Here, we demonstrate that re-
programming human iNKTcells to pluripotency and subse-
quent re-differentiation of functional iNKT-like cells are
possible ex vivo. These regenerated iNKT-like cells are func-
tionally recovered and available in an unlimited supply
from iPSCs. Moreover, they show both the expected
adjuvant function of inducing leukemic antigen-specific
polyclonal cytotoxic T cells via DC activation as well as
TCR-independent direct killing of leukemic cell lines. This
second feature is controlled by NKG2D signaling and,
unexpectedly, DNAM-1 signaling, which is conceivably
enhanced by the lack of TIGITexpression in the re-differen-
tiated iNKT-like cells (re-iNKT cells). The adjuvant property
and newly identified cytotoxic features of re-iNKT cells,
which we demonstrate here against cancer cell lines, may
have wide application in the field of immunotherapy.RESULTS
iNKT Cell-Derived Human iPSCs Are Preferentially
Generated from a CD4+ Subset
Human iNKT cells can be classified into three phenotyp-
ically distinct subsets: CD4-positive (CD4+), CD8-positive214 Stem Cell Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Au(CD8+: CD8ab or CD8aa), and CD4/8 double-negative
(DN) (Brennan et al., 2013). The CD4+ subset has the
potential to produce a large amount of Th2 cytokines,
while the DN and CD8+ subsets have a Th1-biased profile.
In addition, the CD8+ subset produces more IFN-g and
more cytotoxicity than the CD4+ or DN subsets. In this
study, functionally distinct CD4+ and DN iNKT cell lines
were established from the peripheral blood of healthy do-
nors and reprogrammed into iPSCs. We could not
reprogram CD8+ iNKT cells because of an insufficient
number of cells obtained from donor peripheral blood.
However, both CD4+ and DN iNKT cells were efficiently
transduced with defective Sendai virus vectors harboring
four reprogramming factors, OCT3/4, KLF4, SOX2, and
C-MYC (SeVdp(KOSM302L)) (Nishimura et al., 2011)
and SV40 T antigen (SeV18 + SV40T/TS15DF) (Nishimura
et al., 2013), and then formed into embryonic stem cell
(ESC)-like colonies. However, most of the DN iNKT cell-
derived colonies could not be maintained under the
culture conditions used for human pluripotent stem cells,
and those that were maintained showed no differentia-
tion potential toward hematopoietic cells (Figures S1A
and S1B). In addition, the rarely established ESC-like col-
onies derived from DN iNKT cells were positive for resid-
ual Sendai virus vector. In contrast, all established clones
from CD4+ iNKT cells were negative for residual trans-
genes (Figure S1C), showed pluripotency characterized
by the expression of pluripotency-related genes (Fig-
ure S1D) and teratoma formation in immunodeficient
mice (Figure S1E), and were confirmed to have a normal
karyotype (Figure S1F). Although from different donors,
all established clones showed the same TCRa chain
with an invariant Va24-Ja18 (TRAV10*01-TRAJ18*01)
junctional sequence, which is a distinctive feature of
human iNKT cells (Table 1).
Va24-Ja18/Vb11 TCR-Expressing T Cells Can Be
Re-differentiated in the Presence of IL-15 and
Expanded by TCR Stimulation
In contrast to conventional abT cells, whose differentia-
tion is controlled via TCR ligation by specific peptide an-
tigens presented by polymorphic HLA molecules on
thymic epithelial cells (Shah and Zuniga-Pflucker, 2014),
iNKT cells differentiate in a unique fashion within the
thymus (Godfrey et al., 2010). Once early T cell pro-
genitors obtain the Va24 invariant TCR at the
CD4+CD8+ double-positive (DP) stage, they become
sensitive to stimulation by specific glycolipid antigens
presented by the non-polymorphic molecule CD1d. In
addition, they become sensitive to self-stimulation by
CD150, also known as SLAM (signaling lymphocytic acti-
vation molecule) (Veillette et al., 2007). Cytokine depen-
dency during differentiation differs slightly between abTthors
Table 1. Junction Sequences of TCR Genes in Reprogrammed and Redifferentiated Cells
Clone Productivity TRAV TRAJ 30 Va P(N) 50 Ja Frequency
V-J Junction Sequence of Rearranged TRA Genes in the Genome of CD4+ iNKT-iPSC
1 productive 10*1 18*01 TGTGTGGTGAGCG ACAGAGGCTCAACCCTGGGGAGGCTATACTTT 5/8 productive
productive 30*01 10*01 TG TGGCACAGAGAGG ACGGGAGGAGGAAACAAACTCACCTTT 3/8 productive
2 productive 10*01 18*01 TGTGTGGTGAGC GACAGAGGCTCAACCCTGGGGAGGCTATACTTT 1/1 productive
4 productive 10*01 18*01 TGTGTGGTGAGC GACAGAGGCTCAACCCTGGGGAGGCTATACTTT 1/1 productive
8 productive 10*01 18*01 TGTGTGGTGAGCG ACAGAGGCTCAACCCTGGGGAGGCTATACTTT 5/10 productive
productive 30*01 10*01 TG TGGCACAGAGAGG ACGGGAGGAGGAAACAAACTCACCTTT 5/10 productive
V-J Junction Sequence of Rearranged TRA mRNAs of Re-iNKT Cells
1 productive 10*1 18*01 TGTGTGGTGAGCG ACAGAGGCTCAACCCTGGGGAGGCTATACTTT 9/13 productive
productive 30*01 10*01 TG TGGCACAGAGAGG ACGGGAGGAGGAAACAAACTCACCTTT 4/13 productive
2 productive 10*01 18*01 TGTGTGGTGAGC GACAGAGGCTCAACCCTGGGGAGGCTATACTTT 5/5 productive
4 productive 10*01 18*01 TGTGTGGTGAGC GACAGAGGCTCAACCCTGGGGAGGCTATACTTT 2/2 productive
8 productive 10*01 18*01 TGTGTGGTGAGCG ACAGAGGCTCAACCCTGGGGAGGCTATACTTT 6/12 productive
productive 30*01 10*01 TG TGGCACAGAGAGG ACGGGAGGAGGAAACAAACTCACCTTT 6/12 productive
Clone Productivity TRBV TRBD TRBJ 30 Vb N1-P-Db-N2 50 Jb Frequency
V-D-J Junction Sequence of Rearranged TRB Genes in Genome of CD4+ iNKT-iPSC
1 productive 25-1*01 1*01 1-5*01 TGTGCCAGCAGTGAA CTAGGGGAGAATTTG CAGCCCCAGCATTTT 6/6 productive
unproductive – 1*01 1-6*01 – GGGTGCCGATGGAAT TTCACCCCTCCACTTT
2 productive 25-1*01 1*01 2-3*01 TGTGCCAGCAGTG GCAGGAGCCTAAA CACAGATACGCAGTATTTT 2/2 productive
unproductive germline 1*01 2-7*01 TACAAAGCTGTAACATTGTG GGGACAGGGGGCCGC TCCTACGAGCAGTACTTCGGGCCGG
4 productive 25-1*01 1*01 2-3*01 TGTGCCAGCAG GGGATCCGGGACAGGGGCC GATACGCAGTATTTT 4/4 productive
unproductive 11-1*01 – 2-6*01 GGCAG – CAGG
8 productive 25-1*01 1*01 1-5*01 TGTGCCAGCAGTGAA CTAGGGGAGAATTTG CAGCCCCAGCATTTT 6/6 productive
unproductive – 1*01 1-6*01 – GGGTGCCGATGGAAT TTCACCCCTCCACTTT
V-D-J Junction Sequence of Rearranged TRB mRNAs of Re-iNKT Cells
1 productive 25-1*01 1*01 1-5*01 TGTGCCAGCAGTGAA CTAGGGGAGAATTTG CAGCCCCAGCATTTT 5/5 productive
2 productive 25-1*01 1*01 2-3*01 TGTGCCAGCAGTG GCAGGAGCCTAAA CACAGATACGCAGTATTTT 5/6 productive
productive 12-3*01 2*01 2-3*01 TGTGCCAGCAGTT CTTCATCCACTCCCGTC GATACGCAGTATTTT 1/6 productive
4 productive 25-1*01 1*01 2-3*01 TGTGCCAGCAG CGGATCCGGGACAGGGGCC GATACGCAGTATTTT 5/5 productive
unproductive 7-9*04 1*01 2-1*01 AGAGA CACAGGCAGGGAA GGGCC
unproductive 20-1*03 – 2-2P*01 GATGG – AGAGG
8 productive 25-1*01 1*01 1-5*01 TGTGCCAGCAGTGAA CTAGGGGAGAATTTG CAGCCCCAGCATTTT 6/7 productive
productive 20-1*01 2*01 2-7*01 TGCAGTGCTAGA TCCTACTTGGGGGGAGAA GAGCAGTACTTC 1/7 productiveand iNKT cells, as IL-15 is crucial for iNKT cell differentia-
tion (Gordy et al., 2011). When iNKT-iPSCs were differen-
tiated into T-lineage cells without IL-15, they stayed at theStem CeCD4CD8 DN stage but were partially positive for iNKT
cell-related molecules, including CD56, CD69, CD161
(NKRP1; NK cell-related protein 1), CD314 (cellularll Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Authors 215
(legend on next page)
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stress-ligand receptor NKG2D), and invariant TCR
(stained by 6B11, a monoclonal antibody (mAb) specific
for the invariant Va24-Ja18 CDR3 loop), and expressed
low levels of CD150 and CD122 (IL-2/-15 receptor
b chain) at the third week of culture on OP9/DL1 (Fig-
ure 1A). Although they expressed invariant TCR, iPSC-
derived differentiating cells showed minimal expansion
upon stimulation by a-GalCer-loaded peripheral blood
mononuclear cells (PBMCs) (data not shown). This
prompted us to speculate whether other signals, such as
IL-15 and/or SLAM-SLAM interaction, were necessary for
further maturation. In light of the positive feedback effect
of IL-15 signaling on CD122 expression (Castillo et al.,
2010), which may induce further maturation, we modi-
fied the culture medium, adding 10 ng/ml IL-15 from
the second or third week of culture on OP9/DL1.
Improving the culture conditions led to greater numbers
of invariant TCR-positive cells, and a fraction of these
cells showed further enhancement of CD56, CD69,
CD122, CD150, CD161, and CD314 expression (Fig-
ure 1A). It is generally difficult to exactly identify con-
trol/check points (the expressions of TCR or NK markers)
or immature stages in the differentiation process (Godfrey
and Berzins, 2007), since the differentiation of TCR pre-re-
arranged iPSC-derived hematopoietic cells into T-lineage
cells on OP9/DL1 deviates from normal T-lymphopoiesis
(Nishimura et al., 2013; Vizcardo et al., 2013). We were
able to confirm, however, that additional IL-15 induced
further maturation past control/check point 2 to differen-
tiating cells (Figures S2A and S2B). By adding IL-2 to the
culture, we increased cell numbers 7.5-fold over that
seen with IL-15 alone (n R 3). In subsequent experi-
ments, therefore, we cultured re-differentiated T cells
with a combination of Flt3L (FMS-like tyrosine kinase 3
ligand), IL-7, IL-2, and IL-15 (Figure 1B).Figure 1. Re-differentiation of iNKT Cells from iNKT-iPSCs
(A) Surface antigen profiles of re-differentiating T cells from CD4+ iNKT
the indicated cytokines. The results shown are representative of four
patterns of the cells gated by CD45, CD3, and 6B11.
(B) Schematic illustration showing the culture protocol for iNKT cell
ation medium: Iscove’s modified Dulbecco’s medium supplemented wit
5.5 mg/ml human transferrin, 5 ng/ml sodium selenite, 2 mM L-glu
OP9 medium: a-MEM supplemented with 15% FBS, 2 mM L-glutamine
(C) Fold expansion of parental CD4+ iNKT cells and newly induced re
PBMCs. The result obtained with each indicated cell in three indepen
parental clone and subclone of donor A; experiment 2: clone 1, clone 8
clones of donor A and B. Horizontal lines indicate medians. NS, not s
(D) Co-expression profile of PD-1 and TIGIT on re-iNKT cells and paren
The results shown are representative of two independent experiment
(E) Telomere length in parental CD4+ iNKT cells and induced re-iNKT
from three independent experiments that include data from three dif
clones (donor A and donor B) are shown as filled diamonds, squares
compare results from the same donor; *p < 0.05.
Stem CeVa24-Ja18/Vb11 TCR-expressing re-differentiated T cells
were stained with a-GalCer/CD1d tetramer to the same
degree as the parental iNKT cells (Figure S2C) and were
responsive to stimulation with a-GalCer-pulsed PBMCs.
Although there were some differences in the responsive-
ness to stimulation among iNKT-iPSC clones, the final yield
after around 2 weeks was nearly the same as that of the
parental iNKT cells (Figure 1C). In addition, repeated stim-
ulation with a-GalCer-pulsed PBMCs or the mitogen
phytohemagglutinin (PHA-P) in vitro resulted in expan-
sion of the initial cell number by about 103- to 104-fold (Fig-
ure S2D). Because of their phenotypic and functional
similarity to iNKT cells, the re-differentiated T cells ex-
pressing Va24-Ja18/Vb11 TCR are hereafter referred to as
‘‘re-iNKT cells.’’
Generation of iNKT-like Cells through
Reprogramming
Based on previous reports (Johnston et al., 2014; Postow
et al., 2015) and our previous observations of CD8+ T cell
rejuvenation through reprogramming (Nishimura et al.,
2013), we estimated reprogramming-mediated functional
recovery by comparing the expression of the immu-
nological exhaustion-related checkpoint proteins PD-1
(programmed cell death protein 1) and TIGIT (T cell immu-
noreceptor with immunoglobulin and ITIM domains) and
cell exhaustion-related telomere length in expanded re-
iNKT cells with those in parental CD4+ and DN iNKT cells.
Middle to high expression of PD-1 and TIGIT was observed
in both CD4+ and DN iNKT cells, whereas re-iNKT cells ex-
pressed minimal levels of PD-1 and almost no TIGIT, even
after several cycles of expansion induced by TCR stimula-
tion (Figure 1D). The re-iNKT cells also showed a recovery
of telomere length as previously reported (Nishimura
et al., 2013) (Figure 1E).-iPSC (clone 2) on OP9/DL1 feeder cells on day 21 in the presence of
independent experiments examining the surface protein expression
re-differentiation from CD4+ iNKT cell-derived iPSCs. EB differenti-
h 15% fetal bovine serum and a cocktail of 10 mg/ml human insulin,
tamine, 0.45 mM monothioglycerol, and 50 mg/ml ascorbic acid.
, 100 U/ml penicillin, and 100 mg/ml streptomycin.
-iNKT cells around 2 weeks after stimulation with a-GalCer-pulsed
dent experiments is shown as a filled circle. Experiment 1: clone 2,
, and donor A; experiment 3: clone 1, clone 2, clone 8, and parental
ignificant.
tal iNKT cells after TCR stimulation (gated by CD45, CD3, and 6B11).
s. The numbers in the quadrants indicate percentages of cells.
cells normalized to the tetraploid leukemic cell line 1301. Datasets
ferent re-iNKT cell clones (1, 2, and 8), and two parental iNKT cell
, and triangles, respectively. t Tests for paired data were used to
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Figure 2. Gene and Molecular Expression
Profile of Re-iNKT Cells
(A) Flow cytometric analysis of T cells re-
differentiating from CD4+ iNKT-iPSCs on day
10 after TCR stimulation. iPSC-derived re-
differentiating cells were stimulated with
a-GalCer-pulsed (10 ng/ml) and irradiated
PBMCs from an HLA-A24-negative donor.
The results shown are the surface protein
expression patterns of re-differentiating
cells gated by HLA-A24, CD45, CD3, and
6B11, and are representative of four exper-
iments. The blue and red populations in the
right two panels respectively indicate un-
stained and stained samples for the indi-
cated molecules.
(B and C) Global gene expression profiles (B)
and two-way clustering of 53 selected gene
expression profiles (C) related to NK/T cell
differentiation and function for re-iNKT cells
(clones 2 and 4; both from donor B) and
primary immune cells. Levels of mRNA
expression in re-iNKT cells and primary im-
mune cells were determined using RNA
sequencing. Heatmaps show the differential
expression of genes among samples. Red and
blue indicate increased and decreased ex-
pressions, respectively. Blue and red boxes
in (C) indicate gene clusters preferentially
up-regulated in resting and activated re-
iNKT cells, respectively.Gene and Protein Expression Profiles Predict Re-iNKT
Cells to Have the Potential of CD4+ iNKT Cells but Are
Biased toward the Th1-like Phenotype
All expanded re-iNKT cells showed invariant TCR expres-
sion (Figure S2B and Table 1) and expressed CD122 and
CD150 at similar levels. In addition, the activation- and
cytotoxicity-associated molecules CD56, CD69, CD161,
and CD314 were detected in most of the expanded re-
iNKT cells (Figure 2A). Re-iNKT cells also changed their
expression dominance from CD45RA to CD45RO during
a-GalCer-based stimulation, consistent with the effector
memory phenotype (Figure S2E). Although re-iNKT cells218 Stem Cell Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Auwere originally generated from CD4+ iNKT cells, their sur-
face phenotype was more similar to DN iNKT cells. We
therefore analyzed the global gene expression profiles of
re-iNKT cells and other primary lymphoid cell subsets. Hi-
erarchical clustering of transcriptomes enabled by mRNA
sequencing indicated that re-iNKT cells are closest to
freshly isolated iNKT cells and next closest to expanded
iNKT cells after TCR stimulation (Figure 2B). This relation-
ship was confirmed by the hierarchical clustering of
selected genes related to NK/T cells, including 30 transcrip-
tion factors, 13 cytokines, and ten cytokine receptors (Fig-
ures 2C and Table S1). Several genes known to characterizethors
Figure 3. CD1d-Restricted, a-GalCer-Specific Response and
Cytokine Profile of Re-iNKT Cells
(A) IFN-g and IL-4 production. Re-iNKT cells or parental iNKT cells
were co-cultured with DCs in the presence of vehicle or 100 ng/ml
a-GalCer.
(B) Re-iNKT cells were cultured with a-GalCer DCs in the presence of
the indicated blocking Abs. Blockade was assessed based on IFN-g
production.
(C) a-GalCer-dependency and CD1d-restriction. Re-iNKT cells were
cultured with C1R cells expressing mock or the indicated molecules
in the presence of vehicle or 100 ng/ml a-GalCer.
(D) Cytokine profiles. Re-iNKT cells or parental iNKT cells were
stimulated for 24 hr with plate-bound control immunoglobulin G
(IgG) or anti-CD3 mAb (10 mg/ml), after which levels of the indi-
cated cytokines in the culture supernatants were evaluated.
Data were run in triplicate, and the experiment was repeated three
times. The results of one representative experiment are shown.
Error bars depict mean ± SD.
Stem CeiNKTcells, including the innate lymphoid cell-related tran-
scription factor ZBTB16 and the Th1 type pro-inflamma-
tory cytokine and receptor genes IFNG, IFNGR1, and
IL-12RB1, were preferentially expressed in re-iNKT cells
before TCR stimulation (Figure 2C, blue box). On the other
hand, the Th2 helper T cell-related transcription factor
GATA3, the Notch signal-related transcription factor RBPJ,
and the NK/T cell-related cytokine and receptor genes
TNF, IL-5, IL-13, CSF1, and IL2RA were preferentially ex-
pressed in activated re-iNKT cells and expanded primary
iNKT cells (Figure 2C, red boxes). Taken together, these
findings indicate that although re-iNKT cells show a DN
iNKT cell-like surface phenotype, their expression profile
covers CD4+ iNKT cell-related Th1 and Th2 type genes.
Microarray-based DNA methylation analysis was per-
formed to evaluate the epigenetic status of re-iNKT cells.
Correlation plots indicated that the methylation level of
re-iNKT cells was generally higher than that of original
CD4+ or DN iNKT cells, which were similar (Figure S3A).
A detailed profile of each gene revealed that master tran-
scriptional factors of iNKT cells, such as ZBTB16, TBX21,
and GATA3, were similarly methylated among the three
cell populations. Th1-related cytokine genes such as tu-
mor necrosis factor a (TNF-a) and IFN-g were also simi-
larly methylated among the populations, but Th2-related
cytokine genes such as IL-4 and IL-5 were preferentially
methylated in re-iNKT cells. The hypermethylation of
CD4 gene could contribute to the absence of CD4
expression in CD4+ iNKT-iPSC-derived re-iNKT cells
(Figure S3B).
When DCs were used as antigen-presenting cells (APCs),
re-iNKT cells produced IFN-g and negligible amounts of
IL-4 (Figure 3A), and the IFN-g production was inhibited
by the addition of a blocking mAbs specific for CD1d
(Figure 3B). CD1d restriction was also confirmed by usingll Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Authors 219
Figure 4. Induction of Tumor Antigen-Specific CTLs via Re-iNKT Cell-DC Interaction
(A) Re-iNKT cells or parental iNKT cells were stimulated with plate-bound anti-CD3 mAb, after which CD40L expression was evaluated. The
mean fluorescence intensity (MFI) of CD40L is shown.
(B) Vehicle- or a-GalCer DCs were cultured with re-iNKT cells at a DC/re-iNKT cell ratio of 10:1, after which CD86 expression on DCs was
evaluated. The MFI of CD86 is shown. Medium DCs and OK432 DCs served as references.
(legend continued on next page)
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C1R-CD1d as the APC (Figure 3C). When anti-CD3 mAb
was used for TCR stimulation, re-iNKT cells produced
both Th1 and Th2 cytokines, including IL-2, IL-4, IL-5,
IL-13, GM-CSF (granulocyte macrophage colony-stimu-
lating factor), IFN-g, and TNF-a, just as parental CD4+
iNKT cells do (Figures 3D and S4). The IFN-g/IL-4 ratio in
re-iNKT cells stimulated with anti-CD3 mAb was higher
than that in parental iNKT cells, indicating that re-iNKT
cells had a more Th1-biased profile than the parental cells
(Figures 3A, 3D, and S4).
Activation of Re-iNKT Cells Induces DC Maturation
and Downstream Activation of Both Cancer Antigen-
Specific CTLs and NK Cells
iNKT cells significantly influence the efficacy of immune
responses by modulating DC function. CD40L molecules
expressed by activated iNKT cells stimulate DCs through
CD40 ligation, which induces DC maturation character-
ized by CD80 (B7-1) and CD86 (B7-2) elevation following
IL-12p70 production (Brennan et al., 2013). IL-12p70 is a
strong NK cell activator and a crucial inducer of functional
antigen-specific Th1 cells and CTL responses (Trinchieri,
2003). We initially confirmed that the stimulation of
TCRs on re-iNKT cells using immobilized anti-CD3 mAb
activated the cells and enhanced surface CD40L expression
(Figure 4A). Thereafter, vehicle DCs or a-GalCer DCs were
co-cultured with re-iNKT cells, and the expression of the
co-stimulatory molecule CD86 along with IL-12p70 pro-
duction in the differentially conditioned DCs was evalu-
ated (Figures 4B and 4C). a-GalCer DCs conditioned by
re-iNKT cells (re-iNKT/a-GalCer DCs) expressed higher
levels of CD86 than re-iNKT/vehicle DCs, and re-iNKT/
a-GalCer DCs produced IL-12p70, although at a level lower
than that produced by a-GalCer DCs conditioned by the
parental iNKT cells (iNKT/a-GalCer DCs) (Figure 4C). In
addition, the IL-12p70 production could be inhibited using
a blocking anti-CD1d or anti-CD40L mAb (Figure S5A).
These findings indicate that activated re-iNKT cells are
able to induce DC maturation and IL-12p70 production
via CD40 ligation.(C) IL-12p70 production by DCs stimulated using the indicated cond
(D) Schematic representation of the WT1235–243-specific CTL priming
(E and F) Vehicle- or a-GalCer DCs were cultured with or without re-iNK
cultured with autologous CD8+ T cells ± WT1235–243 peptide. (E) Proli
(F) Increased frequencies of WT1235–243-specific CTLs after repeated st
as a negative control.
(G) Cytotoxic activities of pWT1-primed CD8+ T cells toward C1R-A*24:
the indicated E/T ratios.
(H) Proliferative responses of NK cells (1.03 105) cultured for 48 hr in
co-culture. Medium control and IL-2 (300 IU/ml) plus IL-12 (20 ng/m
In (A), (B), (F), and (G), one representative result from at least two ind
triplicate, and experiments were repeated at least twice; the results of o
Stem CeStudies have shown that iNKTcells act via DCs to provide
help in priming diverse, tumor antigen-specific CD8+
T cells (Brennan et al., 2013). Functional re-iNKT cells
would be extremely useful for preventing tumor escape
from antigen-specificmonoclonal CTLs through tumor an-
tigen mutagenesis if functionality could be confirmed. We
therefore performed CTL priming experiments using a
representative cancer antigen, Wilms’ tumor 1 (WT1) (Fig-
ure 4D) (Cheever et al., 2009). Initially, re-iNKT cells were
co-cultured with vehicle DCs or a-GalCer DCs to induce
DC maturation. The DCs were then loaded with an HLA-
A*24:02-restricted, modified 9-mer peptide derived from
WT1 (WT1235–243), irradiated, and cultured with autolo-
gous CD8+ T cells for antigen-specific priming of CTLs.
After 6 days of culture, we observedmarkedly greater prolif-
eration ofWT1235–243-tetramer-positive CD8
+ Tcells in cul-
tures stimulated by WT1235–243 peptide-loaded a-GalCer
DCs than in cultures stimulated by WT1235–243 peptide-
loaded vehicle DCs (Figures 4E, 4F, and S5B). Moreover,
the CTLs induced by WT1235–243 peptide-loaded a-GalCer
DCs exhibited cytotoxic activity toward WT1235–243 pep-
tide-loaded HLA-A24+ C1R cells, but not toward vehicle-
loaded HLA-A24+ C1R cells (Figure 4G). These data indicate
that re-iNKT cells activated by a-GalCer exert cellular adju-
vant effects that boost tumor antigen-specific polyclonal
CTL responses via DCs and could be useful for developing
re-iNKT cell-based adjuvant therapies. Another important
function of iNKT cells is that they have the potential to
induce downstream activation of NK cells via interaction
with a-GalCer-loaded DCs. As indicated in Figures 4H
and S5C, NK cells up-regulated the activation marker
CD69 and showed effective expansion in the presence
of supernatant from re-iNKT cell/a-GalCer-loaded DC
interaction.
Re-iNKT Cells Show NK Cell-like Cytotoxic Activity
through a Mechanism Dependent on NKG2D and
Enhanced DNAM-1 Pathways
Earlier studies indicate that iNKT cells exhibit perforin- or
TRAIL-mediated cytotoxicity toward some hematopoieticitions.
assay.
T cells (clone 2). Differentially conditioned DCs were irradiated and
ferative responses were measured as [3H]thymidine incorporation.
imulation were determined using WT1 tetramer. HIV tetramer served
02 cells ± WT1 peptide were determined using 51Cr-release assays at
the presence of 25% cell-free supernatants that were from iNKT-DC
l) control served as references.
ependent experiments is shown. In (C), (E), and (H) data were run in
ne representative experiment are shown. Error bars depict mean± SD.
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malignancies and DCs (Metelitsa et al., 2003; Nicol et al.,
2000; Nieda et al., 2001; Takahashi et al., 2000). In addi-
tion, certain NKG2D-expressing DN iNKT cell subsets kill
K562 NK-sensitive cells, which lack CD1d and HLA-I but
are rich in the NKG2D ligands MICA and MICB, and also
express ULBP2 and ULBP4 (Kuylenstierna et al., 2011).
Because the major re-iNKT cell population expresses
NKG2D as well as CD56 and CD161, two other NK
markers, we evaluated the cytotoxic potential of re-
iNKT cells in vitro using 51Cr-release assays. Like the
parental iNKT cells, re-iNKT cells displayed minimal cyto-
toxic activity toward vehicle-pulsed DCs (vehicle DCs)
and only weak cytotoxicity toward a-GalCer-pulsed DCs
(a-GalCer DCs) (Figure 5A). However, in contrast to the
parental iNKT cells, which exhibited little cytotoxicity to-
ward K562 or U937 cells, re-iNKT cells showed remark-
able cytotoxic activity, even at low effector/target (E/T)
ratios (Figure 5B). On the other hand, re-iNKT cells
showed only weak cytotoxicity toward Daudi cells, which
lack NKG2D ligands such as MICA/B, ULBP1, ULBP2,
and ULBP3, and DNAM-1 ligands such as poliovirus re-
ceptor (PVR; CD155) or nectin-2 (PVRL; CD112) (Figures
S6A and S6B). Both re-iNKT cells and parental iNKT cells
expressed intracellular perforin and granzyme B as well as
surface DNAM-1 (CD226) (Figure 5C). However, the
expression of Fas ligand (FasL; CD178), natural cytotox-
icity receptors (NCRs; NKp44 and NKp46), and NKG2D
was restricted to re-iNKT cells and was absent
from parental CD4+ NKT cells (Figure 5C). Blocking
experiments revealed that re-iNKT cells mediated
perforin-, NKG2D-, and DNAM-1-dependent K562 cell
lysis, while U937 cell lysis induced by re-iNKT cells was
mediated mainly by perforin and DNAM-1 (Figure 5D).
These data suggest that re-iNKT cells can kill
cancer cells via NKG2D- and DNAM-1-dependent
mechanisms.
Because DNAM-1 is expressed in both re-iNKT cells and
parental iNKT cells (Figure 5C), we asked why DNAM-1-Figure 5. NKG2D- and DNAM-1 Mediated TCR-Independent Cytoto
Parental CD4+ iNKT cells and re-iNKT cells were stimulated with irradiat
and then expanded and used for the assays.
(A) Cytotoxicity of re-iNKT cells and parental CD4+ iNKT cells toward a
(B) Cytotoxicity of re-iNKT cells and parental CD4+ iNKT cells toward
(C) Expression of cytotoxicity-related molecules in IL-2-pretreated
molecules (open) and isotype-matched controls (filled) is shown. The
(D) Cytotoxicity toward the indicated tumor cell lines at an E/T ratio
receptor/ligand interactions or after pretreating re-iNKT cells with 10
(E) CD96 and TIGIT expression. Re-iNKT cells or parental iNKT cells
(10 mg/ml). Expression of the indicated molecules (open) and isotyp
shown in the upper right corner.
In (C) and (E), one representative result from two to three independ
experiments were repeated twice; the results of one representative e
Stem Cemediated cytotoxicity was restricted to re-iNKT cells. The
ligands for DNAM-1, PVR, and nectin-2 share with
CD96 and TIGIT an inhibitory receptor important for
the modulation of NK cell or CTL function. Both CD96
and TIGIT attenuate effector responses by competitively
inhibiting or interfering with DNAM-1-mediated co-stim-
ulation of CTLs (Chan et al., 2014; Johnston et al., 2014).
Flow cytometric analysis revealed that TIGIT is strongly
expressed on parental iNKT cells but never on re-iNKT
cells, whereas CD96 is expressed on both (Figures 1D
and 5E). These findings suggest that weak expression of
TIGIT on re-iNKT cells may be crucial for enhanced
DNAM-1-mediated target cell killing and that re-iNKT
cells exert cytotoxicity through this mechanism, which
is unlike parental iNKT cells.DISCUSSION
In this study, we demonstrated the regeneration and
expansion of human iNKT cells via iPSCs. Re-iNKT cells
were originally induced from CD4+ iNKT cells, although
re-iNKT cells were CD4CD8 DN and exhibited Th1-
biased properties and cytotoxicity. One possible explana-
tion for this phenotype is that it reflects the effect of
IL-15, which is reportedly indispensable for the proper
development and terminalmaturation of iNKTcells (Gordy
et al., 2011). Indeed, our established protocol, in which
exogenous IL-15 was added, achieved differentiation and
functional maturation of re-iNKT cells through the up-
regulation of T-bet, which accelerates IL-2/-15Rb expres-
sion, leading to differentiation of Th1-biased re-iNKT cells
via a positive feedback effect of IL-15 signaling. The re-
differentiation may depend in part on the aberrant differ-
entiation of progenitor T cells into mature re-iNKT cells.
Specifically, iNKT cells derived from iPSCs never exhibit a
CD4+CD8+ DP stage during in vitro differentiation, which
suggests re-iNKT cells skip that physiological step of iNKTxicity of re-iNKT Cells
ed PBMCs pulsed with a-GalCer in the presence of rhIL-2 and rhIL-15
utologous vehicle DCs and a-GalCer DCs at the indicated E/T ratios.
K562 and U937 cells at the indicated E/T ratios.
re-iNKT cells or parental iNKT cells. Expression of the indicated
MFI of each molecule is shown in the upper right corner.
of 2.5:1 was tested in the presence of the indicated Abs blocking
nM concanamycin A (CMA) to block perforin.
were stimulated with plate-bound control IgG or anti-CD3 mAb
e-matched controls (filled) is shown. The MFI of each molecule is
ent experiments is shown. In (D), data were run in triplicate, and
xperiment are shown. Error bars depict mean ± SD.
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cell differentiation. It is known that some lymphoid cells
with innate-like immune functionality are directly derived
at theCD4CD8DNprogenitor Tcell stage under the con-
trol of the transcriptional repressor ID2. These innate
lymphoid cells, which include NK cells, have been charac-
terized by their effector functionality, and some exhibit
CD4+ T helper cell-like functions that are also observed in
iNKT cell subsets (Brennan et al., 2013; Eberl et al., 2015).
At themoment, we do not knowwhether the normal coun-
terpart of re-iNKT cells is within the innate lymphoid sub-
sets. Further investigation to clarify the mechanism of
re-iNKT cell differentiation will improve the protocol to
generate re-iNKT cells that are completely equivalent to
natural iNKT cells.
It is often pointed out that tumor cells can escape im-
mune cells by changing their antigenicity through the
modification of targeted peptide sequences or reduction
of HLA-molecule expression (Schreiber et al., 2011). This
is usually the case when immune therapies with antigen-
specific monoclonal CTLs fail. Given their functional sim-
ilarity to natural iNKT cells, re-iNKT cells, which would be
available at an unlimited supply, would be expected to
exert cellular adjuvant effects via DCs following the activa-
tion of tumor antigen-specific polyclonal CTLs and NK
cells, although the level of cytokine production induced
by a-GalCer DCswas lower in re-iNKT than in parental cells
and there was less cytokine variety. In addition, the NK
cell-like cytotoxicity of re-iNKT cells could assist with
TCR-independent antitumor responses via NKG2D- and
DNAM-1-mediated direct killing of tumor cells. TIGIT in-
hibits DNAM-1 function via the same ligands not only by
competitively inhibiting ligand binding but also through
direct interaction with DNAM-1, which physically pre-
vents DNAM-1 homodimerization (Johnston et al., 2014;
Stanietsky et al., 2009; Yu et al., 2009). The balance be-
tween DNAM-1 and TIGIT expression may control iNKT
cell cytotoxicity; that is, re-iNKT and parental iNKT cells
express equal levels of DNAM-1, but re-iNKT cells do not
express TIGIT, which may enable stronger cytotoxic
signaling than primary iNKT cells. In addition, TIGIT was
recently identified as a new exhaustion marker expressed
in tumor-infiltrating lymphocytes and is thought to be
an attractive candidate for blockade, along with PD-1, to
reverse CTL dysfunction in cancer (Johnston et al., 2014).
That re-iNKTcells scarcely express TIGITand PD-1 is a prop-
erty that would be beneficial for cells used in cancer immu-
notherapy. In addition, iNKT cells reportedly control the
tumormicroenvironment by killing tumor-associatedmac-
rophages (Song et al., 2009) and converting myeloid-
derived suppressor cells into APCs (De Santo et al., 2010).
The general mechanism of the direct killing activity in re-
iNKT cells is unknown. The low expression and hyperme-
thylation of BCL11B may be partly responsible (Figures224 Stem Cell Reports j Vol. 6 j 213–227 j February 9, 2016 j ª2016 The Au2C and S3B), as the loss of the Bcl11b expression induces
lineage reprogramming from murine T cells to NK cells
(Li et al., 2010). Thus, Th1-biased cytokine production
and direct TCR-independent killing may enable re-iNKT
cells to exert therapeutic effects against the tumormicroen-
vironment. Nevertheless, it will be important to gather
additional therapeutic evidence in vitro and in vivo using
appropriate animal models, as the characteristics and
responsiveness of the re-iNKT cells were not completely
identical to those of parental iNKT cells.
iNKT cells have been implicated in the regulation of im-
mune responses associated with a broad range of diseases,
including autoimmunity, infectious diseases, and cancer,
and their contribution to cell therapy has beenmuch antic-
ipated. Although many technical challenges lie ahead, re-
iNKT cells are expected to open new avenues toward
broadly applicable iNKT cell-based immunotherapies.EXPERIMENTAL PROCEDURES
Preparation of Va24 iNKT Cells and Generation of
iNKT-iPSCs
The preparation of human iNKT cells was as described previously
(Liu et al., 2008). In brief, PBMCs from three healthy donors
were cultured for 15 days in the presence of 10 ng/ml a-GalCer, af-
ter which Va24+6B11+CD4CD8b or Va24+6B11+CD4+CD8b
cells were sorted using a flow cytometer. The sorted cells were
then re-stimulated with irradiated PBMCs pulsed with a-GalCer
in the presence of recombinant human IL-2 (rhIL-2) and rhIL-15.
Establishment and characterization of iPSCs from the iNKT cells
were performed as described previously (Nishimura et al., 2013).
In brief, iNKT cells were stimulated with irradiated PBMCs pulsed
with a-GalCer and transduced with both reprogramming factors
(OCT3/4, KLF4, SOX2, and C-MYC) using SeVdp (KOSM) 302L
and SV40 large T antigen using SeV18 + SV40LTA/TS15DF. Finally,
the cells were cultured for several weeks after removal of the SeV
vectors from the cytoplasm (Nishimura et al., 2011). The entire
study was conducted in accordance with the Declaration of Hel-
sinki and with the approval of institutional ethics boards.
iNKT Cell Differentiation from iNKT-iPSCs
To differentiate iNKT-iPSCs into iNKT cells, we used a previously
described T cell differentiation method with slight modification
(Nishimura et al., 2013). In brief, clumps of iPSCs were transferred
onto C3H10T1/2 feeder cells and cultured in EB medium contain-
ing rhVEGF (vascular endothelial growth factor). On day 7, rhSCF
and rhFlt3L were added to the culture. On day 14, hematopoietic
progenitor cells were collected and transferred onto OP9-DL1 cells
and co-cultured in OP9 medium in the presence of rhIL-7 and
rhFlt3L. On day 29, rhIL-15 and rhIL-2 were added to the culture
(Figure 1B).
Flow Cytometry-Based Assays
Information about the mAbs used for flow cytometry and func-
tional assays are listed in Table S2. Stained cell samples werethors
analyzed using a FACSCalibur or FACSAriaII flow cytometer (BD
Biosciences), and the data were processed using FlowJo (Tree
Star). CD1d-tetramer (Proimmune) and HLA-A*24:02/WT1235–243
tetramer were used to detect iNKT cells and WT1 peptide-specific
CTLs, respectively, with HLA-A*24:02/HIV Env584–592 tetramer
serving as a negative control. Relative telomere length was
measured with a telomere PNA kit/fluorescein isothiocyanate
(DAKO). Levels of human cytokines in the culture supernatants
were evaluated using a bead-based multiplex immunoassay
(FlowCytomix; Affymetrix eBiosciences and BD Cytometric Beads
Array; BD Biosciences) or ELISA (Affymetrix eBiosciences). For the
multiplex assay, data were acquired on a FACSCanto flow cytome-
ter (BD Biosciences).
Cell Proliferation
Cell proliferation was evaluated by direct enumeration of cells and
by using [3H]thymidine incorporation assays as described by Liu
et al. (2008).
CTL Priming and Cytotoxicity Assays
Both parental iNKTcells and re-differentiated iNKTcells were stim-
ulatedwith irradiated PBMCs pulsedwith a-GalCer in the presence
of rhIL-2 and rhIL-15. Vehicle- or a-GalCer-pulsed autologous DCs
were cultured with the cells for 12 hr. The differentially condi-
tioned DCs were then irradiated and cultured with CD8+ T cells
in the presence of WT1235–243 peptide. After 6 days of culture,
the proliferative responses of the cells were measured by [3H]
thymidine incorporation assay. After 10 days of culture, the fre-
quencies of WT1 peptide-specific CTLs were determined using
HLA-A*24:02/WT1235–243 tetramer, and the cells were re-stimu-
lated using irradiated autologous PBMCs pre-pulsed with WT1
peptide in the presence of rhIL-2. After an additional 9 days of
culture, the expansion of WT1 peptide-specific CTLs was deter-
mined. The cytotoxicity of the CTLs and re-iNKT cells was
measured using standard 51Cr-release assays.
RNA Sequencing of Re-iNKT Cells
We extracted total RNA using an RNeasy micro kit (Qiagen) as
instructed by the manufacturer. cDNA was synthesized using a
SMARTer Ultra Low Input RNA for Illumina Sequencing -HV kit
(Clontech), after which the Illumina library was prepared using a
Low Input Library Prep kit (Clontech). The libraries were
sequenced using HiSeq 2500 in 101 cycle Single-Read mode. All
sequence reads were extracted in FASTQ format using BCL2FASTQ
Conversion Software 1.8.4 in the CASAVA 1.8.2 pipeline. The
sequence reads weremapped to hg19 reference genes, downloaded
on December 10, 2012 using TopHat v2.0.8b, and quantified using
RPKMforGenes. The data have been deposited in NCBI Gene
Expression Omnibus (http://www.ncbi.nlm.nih.gov/geo/) and
are accessible through GEO: GSE76371 for gene expression micro-
array and GEO: GSE76372 for genome-wide DNA methylation
analysis.
Statistics
PRISM (GraphPad Software) was used for all statistical analyses.
t Tests forpairedorunpaireddatawereused toassess the significance
of differences between the means of two experimental groups.Stem CeSUPPLEMENTAL INFORMATION
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